285 related articles for article (PubMed ID: 10037029)
1. In relapsed patients after lymphocyte depleted bone marrow transplantation the percentage of donor T lymphocytes correlates well with the outcome of donor leukocyte infusion.
Schattenberg A; Schaap N; Van De Wiel-Van Kemenade E; Bär B; Preijers F; Van Der Maazen R; Roovers E; De Witte T
Leuk Lymphoma; 1999 Jan; 32(3-4):317-25. PubMed ID: 10037029
[TBL] [Abstract][Full Text] [Related]
2. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation.
Drobyski WR; Hessner MJ; Klein JP; Kabler-Babbitt C; Vesole DH; Margolis DA; Keever-Taylor CA
Blood; 1999 Jul; 94(2):434-41. PubMed ID: 10397710
[TBL] [Abstract][Full Text] [Related]
3. Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion.
Sehn LH; Alyea EP; Weller E; Canning C; Lee S; Ritz J; Antin JH; Soiffer RJ
J Clin Oncol; 1999 Feb; 17(2):561-8. PubMed ID: 10080600
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of leukemia relapsed after allogenic bone marrow transplantation with donor lymphocyte infusion: report of 11 cases].
Sanz Rodríguez C; Steegmann JL; Granda A; de la Cámara R; Figuera A; Arranz R; Gómez-García de Soria V; Alegre A; Fernández-Rañada JM
Sangre (Barc); 1999 Dec; 44(6):456-63. PubMed ID: 10822760
[TBL] [Abstract][Full Text] [Related]
5. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.
Alyea EP; Soiffer RJ; Canning C; Neuberg D; Schlossman R; Pickett C; Collins H; Wang Y; Anderson KC; Ritz J
Blood; 1998 May; 91(10):3671-80. PubMed ID: 9573003
[TBL] [Abstract][Full Text] [Related]
6. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA
Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
[TBL] [Abstract][Full Text] [Related]
7. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: indications and dose escalation.
Shiobara S; Nakao S; Ueda M; Yamazaki H; Takahashi S; Asano S; Yabe H; Kato S; Imoto S; Maruta A; Yoshida T; Gondo H; Morishima Y; Kodera Y
Ther Apher; 2001 Feb; 5(1):40-5. PubMed ID: 11258609
[TBL] [Abstract][Full Text] [Related]
8. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation.
Giralt S; Hester J; Huh Y; Hirsch-Ginsberg C; Rondón G; Seong D; Lee M; Gajewski J; Van Besien K; Khouri I; Mehra R; Przepiorka D; Körbling M; Talpaz M; Kantarjian H; Fischer H; Deisseroth A; Champlin R
Blood; 1995 Dec; 86(11):4337-43. PubMed ID: 7492795
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow transplantation depleted of T cells followed by repletion with incremental doses of donor lymphocytes for relapsing patients with chronic myeloid leukemia: a therapeutic strategy.
Novitzky N; Rubinstein R; Hallett JM; du Toit CE; Thomas VL
Transplantation; 2000 Apr; 69(7):1358-63. PubMed ID: 10798754
[TBL] [Abstract][Full Text] [Related]
10. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome.
Shiobara S; Nakao S; Ueda M; Yamazaki H; Takahashi S; Asano S; Yabe H; Kato S; Imoto S; Maruta A; Yoshida T; Gondo H; Morishima Y; Kodera Y
Bone Marrow Transplant; 2000 Oct; 26(7):769-74. PubMed ID: 11042659
[TBL] [Abstract][Full Text] [Related]
11. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
[TBL] [Abstract][Full Text] [Related]
12. Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse.
Choi SJ; Lee JH; Lee JH; Kim S; Seol M; Lee YS; Lee JS; Kim WK; Chi HS; Lee KH
Leukemia; 2004 Nov; 18(11):1789-97. PubMed ID: 15385924
[TBL] [Abstract][Full Text] [Related]
13. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
Collins RH; Shpilberg O; Drobyski WR; Porter DL; Giralt S; Champlin R; Goodman SA; Wolff SN; Hu W; Verfaillie C; List A; Dalton W; Ognoskie N; Chetrit A; Antin JH; Nemunaitis J
J Clin Oncol; 1997 Feb; 15(2):433-44. PubMed ID: 9053463
[TBL] [Abstract][Full Text] [Related]
14. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions.
Porter DL; Collins RH; Hardy C; Kernan NA; Drobyski WR; Giralt S; Flowers ME; Casper J; Leahey A; Parker P; Mick R; Bate-Boyle B; King R; Antin JH
Blood; 2000 Feb; 95(4):1214-21. PubMed ID: 10666193
[TBL] [Abstract][Full Text] [Related]
15. Red blood cell phenotyping is a sensitive technique for monitoring chronic myeloid leukaemia patients after T-cell-depleted bone marrow transplantation and after donor leucocyte infusion.
Schaap N; Schattenberg A; Bär B; Mensink E; de Man A; Geurts van Kessel A; de Witte T
Br J Haematol; 2000 Jan; 108(1):116-25. PubMed ID: 10651734
[TBL] [Abstract][Full Text] [Related]
16. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E;
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
[TBL] [Abstract][Full Text] [Related]
17. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation.
Bär BM; Schattenberg A; Mensink EJ; Geurts Van Kessel A; Smetsers TF; Knops GH; Linders EH; De Witte T
J Clin Oncol; 1993 Mar; 11(3):513-9. PubMed ID: 8445426
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy and granulocyte colony stimulating factor-mobilized blood cell infusion followed by interferon-alpha for relapsed malignancy after allogeneic bone marrow transplantation.
Grigg A; Kannan K; Schwarer AP; Spencer A; Szer J
Intern Med J; 2001; 31(1):15-22. PubMed ID: 11478351
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: superior outcomes compared with chemotherapy alone and an analysis of prognostic factors.
Yan CH; Wang JZ; Liu DH; Xu LP; Chen H; Liu KY; Huang XJ
Eur J Haematol; 2013 Oct; 91(4):304-14. PubMed ID: 23837640
[TBL] [Abstract][Full Text] [Related]
20. Donor chimerism does not predict response to donor lymphocyte infusion for relapsed chronic myelogenous leukemia after allogeneic hematopoietic cell transplantation.
Chiorean EG; DeFor TE; Weisdorf DJ; Blazar BR; McGlave PB; Burns LJ; Brown C; Miller JS
Biol Blood Marrow Transplant; 2004 Mar; 10(3):171-7. PubMed ID: 14993882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
